Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 1020 results for "novartis"

Array acquires worldwide rights to encorafenib from Novartis
Pharma Letter

Array BioPharma (ARRY) To Acquire Global Rights For Novartis (...

Array Biopahrma Inc. ( NASDAQ:ARRY ) has agreed to acquire worldwide rights for Novartis cancer drug, encorafenib (LGX818), an investigational BARF inhibitor in its late stage clinical trials. The company stock shot up over 40% on Friday, following ... Bidness Etc, 20 hours ago
This is Money

A revived GlaxoSmithKline is back on target with Novartis deal - so are the shares in Britain's biggest drug firm now worth a punt?

By Published: 1 View comments After what many would acknowledge as an annus horribilis, GlaxoSmithKline chief executive Sir Andrew Witty must have been relieved to see the back of 2014. It was a year in which the pharmaceutical firm's shares ...
 This is Money21 hours ago NOVARTIS : Daily Mail, London, Investment Extra column  4 Traders1 day ago INVESTMENT EXTRA: A revived GlaxoSmithKline is back on target  This is Money1 day ago Daily Mail, London, Investment Extra column [Daily Mail, London]  BusinessWeek1 day ago

FDA clears Novartis meningitis vaccine

News Editor The FDA approves Novartis' (NYSE:NVS) Bexsero, a vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals ages 10 through 25. This approval, including Pfizer's clearance in ...
 Seeking Alpha1 day ago Novartis: CHMP Adopts Positive Opinion For Jakavi - Quick Facts  RTTNews.com2 days ago Array buying Novartis BRAF inhibitor for (almost) no money down  Scrip1 day ago News Scan for Jan 23, 2015  Centre For Infectious Disease Research and Policy1 day ago

Array to Acquire Rights to Novartis Cancer Drug

- US-based biopharmaceutical company Array BioPharma Inc According to the parties, this agreementis conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC onApril 22, 2014, which are expected to close in the first ...
 BusinessWeek1 day ago Array Biopharma : BRIEF: Shares of Boulder-based Array jump after drug agreement with Novartis  4 Traders1 day ago Array Biopharma : shares jump after drugmaker details Novartis deal  4 Traders1 day ago Array BioPharma shares jump on news of Novartis cancer-drug deal  Yahoo! News15 hours ago

Profit Expected to Dip for Novartis

Despite an expected dip in profit, analysts are generally optimistic about Novartis as it prepares to reports its fourth-quarter earnings on Tuesday, January 27, 2015. The consensus earnings per share estimate is $1.13 per share. The consensus ...
 Forbes.com1 day ago

Novartis CEO says reviewing Swiss costs after franc shock

Jan 22 (Reuters) - Novartis will review its Swiss cost base after the country's central bank scrapped a cap on the franc last week, sending the currency soaring, the Swiss drugmaker's chief executive said on Thursday. "We'll have to take a hard ...
 Reuters2 days ago Novartis AG CEO Taking a Hard Look at Swiss Costs, Possible Bolt-On Acquisitions  BioSpace1 day ago Video: We are funding part of ACA: Novartis CEO  NBCNews.com2 days ago Novartis CEO says reviewing Swiss costs on franc shock  The Gulf Today1 day ago

Novartis AG (NVS) Trading Near $97.12 Support Level

After closing Wednesday at $98.75, Novartis AG ("NVS) presents an attractive opportunity to get a 2.90% return in just 176 days, which is an annualized return of 6.02% (for comparison purposes only).
 Individual.com2 days ago Novartis AG (NVS) Showing Bullish Technicals With Resistance At $102.68  Individual.com4 days ago

BRIEF-Aspen Pharmacare buys rights to Novartis anti-coagulant Mono-Embolex

Jan 23 (Reuters) - Aspen Pharmacare Holdings Ltd * Acquisition of rights to an anti-coagulant product from Novartis * Has entered into an agreement with Novartis AG in terms of which it will acquire rights to Mono-Embolex * Deal ...
 Reuters Africa2 days ago Aspen Pharmacare Ltd. Grabs Rights to Novartis AG's Mono-Embolex for $142.3 Million  BioSpace1 day ago

After Yesterday's Decline of 1.93%, Novartis Offers Investors Better Value

Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $95.86 to a high of $97.11. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $98.10 on volume of 3.0 million shares. Often times after ...
 Individual.com2 days ago SmarTrend Watching for Potential Rebound in Shares of Novartis After 1.93% Loss  Comtex SmarTrend2 days ago

FTC Approves Novartis-GSK Deal; Former Asked to Divest Nicotine Patch Business

The Federal Trade Commission has finally approved the joint venture of Novartis AG (ADR) ( NYSE:NVS ) and GlaxoSmithKline Plc (ADR) ( NYSE:GSK) in consumer health products, and Novartis has agreed to divest its Habitrol line of nicotine patches. ...
 Bidness Etc3 days ago FTC Approves Novartis/GSK OTC Venture But Novartis Must Divest Nicotine Patch Biz  Pharmaceutical Manufacturing Magazine2 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less